Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/12/24
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity SummitGlobeNewsWire • 03/06/24
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical OfficerGlobeNewsWire • 02/28/24
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/06/24
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/02/24
Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark CloudsSeeking Alpha • 01/29/24
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024GlobeNewsWire • 01/26/24
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)GlobeNewsWire • 01/09/24
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GUGlobeNewsWire • 12/18/23
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 12/01/23
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/07/23
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual MeetingGlobeNewsWire • 11/02/23
Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023GlobeNewsWire • 10/17/23
Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701GlobeNewsWire • 10/16/23
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert' Series (Session 2) on CRB-701 on October 10, 2023GlobeNewsWire • 10/03/23
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual MeetingPRNewsWire • 09/27/23